Cargando…
Age-Related Medicine
A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges of developing medicines for older adults. International experts discussed the complexity introduced by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as an individual...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523864/ https://www.ncbi.nlm.nih.gov/pubmed/30970554 http://dx.doi.org/10.3390/pharmaceutics11040172 |
_version_ | 1783419433217163264 |
---|---|
author | Wahlich, John Orlu, Mine Mair, Alpana Stegemann, Sven van Riet-Nales, Diana |
author_facet | Wahlich, John Orlu, Mine Mair, Alpana Stegemann, Sven van Riet-Nales, Diana |
author_sort | Wahlich, John |
collection | PubMed |
description | A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges of developing medicines for older adults. International experts discussed the complexity introduced by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as an individual ages. The way in which regulatory authorities are encouraging the development of age-appropriate medicines was highlighted. Examples were provided of the difficulties faced by the older population with some medicinal products and suggestions given as to how the pharmaceutical scientist can build the requirements of the older population into their development of new medicines, as well as improvements to existing ones. |
format | Online Article Text |
id | pubmed-6523864 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65238642019-06-04 Age-Related Medicine Wahlich, John Orlu, Mine Mair, Alpana Stegemann, Sven van Riet-Nales, Diana Pharmaceutics Meeting Report A meeting organised by the Academy of Pharmaceutical Sciences focussed on the challenges of developing medicines for older adults. International experts discussed the complexity introduced by polypharmacy and multiple morbidities and how the risk–benefit ratio of a medicine changes as an individual ages. The way in which regulatory authorities are encouraging the development of age-appropriate medicines was highlighted. Examples were provided of the difficulties faced by the older population with some medicinal products and suggestions given as to how the pharmaceutical scientist can build the requirements of the older population into their development of new medicines, as well as improvements to existing ones. MDPI 2019-04-09 /pmc/articles/PMC6523864/ /pubmed/30970554 http://dx.doi.org/10.3390/pharmaceutics11040172 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Meeting Report Wahlich, John Orlu, Mine Mair, Alpana Stegemann, Sven van Riet-Nales, Diana Age-Related Medicine |
title | Age-Related Medicine |
title_full | Age-Related Medicine |
title_fullStr | Age-Related Medicine |
title_full_unstemmed | Age-Related Medicine |
title_short | Age-Related Medicine |
title_sort | age-related medicine |
topic | Meeting Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6523864/ https://www.ncbi.nlm.nih.gov/pubmed/30970554 http://dx.doi.org/10.3390/pharmaceutics11040172 |
work_keys_str_mv | AT wahlichjohn agerelatedmedicine AT orlumine agerelatedmedicine AT mairalpana agerelatedmedicine AT stegemannsven agerelatedmedicine AT vanrietnalesdiana agerelatedmedicine |